The synthesis and cytotoxic evaluation of a series of benzodioxole substituted titanocenes

Sweeney, Nigel J.; Claffey, James; Müller‐Bunz, Helge; Pampillón, Clara; Strohfeldt, Katja; Tacke, Matthias

doi:10.1002/aoc.1177

Cited by 25 publications

(20 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A novel approach to obtain new titanocene antitumoral drugs start from fulvenes [24][25][26][27][28][29][30][31][32][33][34][35] and other precursors [34][35][36][37][38]. This strategy gives a direct access to highly substituted titanocenes via reductive dimerisation, carbolithiation or hydrodolithiation of the fulvene followed by transmetallation in the last two cases.…”

Section: Anticancer Titanocenesmentioning

confidence: 99%

Organometallic Complexes: New Tools for Chemotherapy

Chavain¹,

Biot²

2010

CMC

View full text Add to dashboard Cite

The importance of organometallics can be noticed by their presence in all life organisms. The most known natural organometallic molecule is vitamin B12, a porphyrin containing a cobalt atom, useful for several enzymatic transformations. Based on the remarkable properties of this class of compounds, a new area of medicinal research was developed. Gérard Jaouen was the first to introduce the term of "bioorganometallic chemistry" in 1985 although the first organometallic therapeutical was Salvarsan®, discovered by Paul Ehrlich (Nobel Prize in Medicine in 1908). Bioorganometallic chemistry consists of the synthesis and the study of organometallic complexes, complexes with at least one metal-carbon bond, in a biological and medicinal interest. This field of research was accentuated by the discovery of the ferrocene in 1951 by Pauson and Kealy, confirmed in 1952 by Wilkinson (Nobel Prize in 1973). Today, bioorganometallic chemistry includes 5 main domains: (1) organometallic therapeuticals, (2) toxicology and environment, (3) molecular recognition in aqueous phases, (4) enzymes, proteins and peptides, (5) bioanalysis and pharmaceutical sensors. In this review, we focused on organometallic therapeuticals. The exceptional properties of organometallics are first described and then, an overview on the main organometallic complexes used for drug design is presented. This review gives an idea how organometallics can be used for the rational design of new drugs.

show abstract

Section: Anticancer Titanocenesmentioning

confidence: 99%

Organometallic Complexes: New Tools for Chemotherapy

Chavain¹,

Biot²

2010

CMC

View full text Add to dashboard Cite

show abstract

“…However, the efficacy of the metallocene dihalide proved to be too low to warrant further clinical trials. In order to increase the cytotoxicity, a variety of titanocene derivatives Cp 0 2 TiX 2 with substituted Cp ligands [5][6][7][8][9][10][11][12][13][14][15] or modified leaving groups X [16,17] have been synthesised in recent years. The titanocene derivative bis-[(p-methoxybenzyl)cyclopentadienyl]titanium(IV) chloride ([(g 5 -C 5 H 4 -CH 2 -C 6 H 4 -OCH 3 ) 2 TiCl 2 ], Titanocene Y, Fig.…”

Section: Introductionmentioning

confidence: 99%

Binding and hydrolysis studies of antitumoural titanocene dichloride and Titanocene Y with phosphate diesters

Erxleben

Claffey

Tacke

2010

Journal of Inorganic Biochemistry

Self Cite

View full text Add to dashboard Cite

“…More recently, novel methods starting from fulvenes and other precursors [7,8] allow direct access to anti-proliferative titanocenes via reductive dimerisation with titanium dichloride [9][10][11][12][13], hydridolithiation [14][15][16][17] or carbolithiation [18][19][20][21][22][23][24][25][26] of the fulvene followed by transmetallation with titanium tetrachloride in the latter two cases.…”

Section: Introductionmentioning

confidence: 99%